Month: July 2021

The digital health platform will provide the infrastructure to support the conscious and trustworthy adoption of psychedelics DENVER, July 13, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), is launching the 2.0 version of its virtual health platform on July 30, 2021 (see Mindleap.com), which provides the infrastructure to support the conscious and trustworthy adoption of psychedelics into the broader categories of mental health and inner wellness. “We are providing a platform that can help transform the lives of millions of people,”...

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that Gayle Gironda has been appointed as senior vice president of human resources. Ms. Gironda is a human resources leader with more than 20 years of experience in organizational design, talent recruitment, performance culture, planning and leadership development. “Gayle brings a deep knowledge of life sciences, stemming from her work across large multinational pharmaceutical organizations and small biotech companies, and a passion for supporting people living with rare diseases,” said Axel Bolte, MSc, MBA, co-founder, president and chief executive officer of Inozyme Pharma. “We are thrilled to welcome her to the team as...

~ Study Confirms Long-Term Treatment with KEVEYIS is Safe and Effective for Chronic Use ~ ~ Analyses Provide Potentially Useful Information to Help Guide Clinician Patient Counseling & Management When Starting Treatment with KEVEYIS ~ DUBLIN, Ireland and TREVOSE, Pa., July 13, 2021 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that post hoc analyses from a one year open-label study evaluating daily use of KEVEYIS® (dichlorphenamide) for the treatment of Primary Periodic Paralysis (PPP) following a nine-week randomized, controlled study were published in the peer-reviewed journal, Muscle & Nerve. The results confirmed that long-term...

Equipped with Vision Marine’s Proprietary Powertrain Technology, E-Motion™ MONTREAL, July 13, 2021 (GLOBE NEWSWIRE) — Vision Marine Technologies, Inc. (Nasdaq: VMAR) (“Vision Marine” or the “Company”), a leading manufacturer in the electric recreational boating industry serving both OEMs and consumers, is pleased to announce today that the Company will partner with Shaun Torrente of Shaun Torrente Racing to pilot the Hellkats 32’ Super-Sport Widebody Catamaran, equipped with a twin application of Vision Marine’s groundbreaking E-Motion™ powertrain system. Shaun Torrente is an integral part of our plan to achieve the world’s fastest electric boat, powered by E-Motion™, the world’s most powerful electric outboard. Mr. Torrente will apply his experience as a multi-series World Powerboat Champion and manufacturer of marine components,...

CAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the dosing of the first patient in its TiTAN study, a Phase 1/2a clinical trial testing its GEN-011 therapy. GEN-011 represents a new category of autologous solid tumor cell therapy: neoantigen-targeted peripheral T cells (“NPTs”). “Dosing the first patient with GEN-011 represents an exciting milestone for Genocea and the field of neoantigen-targeted T cell therapy,” said Thomas Davis, M.D., the company’s Chief Medical Officer. “We believe our GEN-011 therapy employs better targeting – using our ATLAS™ platform to select optimal neoantigen targets that drive anti-tumor immune responses and avoid immunosuppressive Inhibigens™ – and better...

Dallas, July 13, 2021 (GLOBE NEWSWIRE) — Thryv Holdings, Inc. (NASDAQ:THRY), the provider of Thryv® , the end-to-end customer experience platform for growing small businesses, and Hub by Thryv™, the leading platform for emerging franchises, is proud to announce it continues to win industry awards in key categories, as determined by verified software user reviews.  G2, an online marketplace where software users can discover and review technology, has ranked Thryv a Leader for small businesses for the seventh quarter in a row. Thryv has once again been named an overall Leader among competitors in G2’s Summer 2021 Reports.  Additional G2 Summer Report 2021 Leadership Awards for Thryv include: For the second quarter, Small Business users say Thryv is the Easiest to Use. Making it the fourth quarter in a row, Thryv has the Highest...

BEIJING, July 13, 2021 (GLOBE NEWSWIRE) — 36Kr Holdings Inc. (“36Kr” or the “Company”) (NASDAQ: KRKR), a prominent brand and pioneering platform dedicated to serving New Economy participants in China, today announced that it has joined hands with NIO, a pioneer in China’s premium electric vehicle market, to launch a business-centric podcast series titled Kr-Intelligence on NIO Radio, an interactive audio community operated by NIO. Nio Inc. (NYSE: NIO) is a pioneer and a leading manufacturer of premium smart electric vehicles in China with the mission of shaping a joyful life. NIO Radio is a media channel exclusively for NIO users that runs 24/7. As an audio program focused on business information and knowledge sharing, Kr-Intelligence will be broadcast on the NIO Radio playlist with a spotlight on the latest business trends, presenting...

Clinical Trial Now Expands to Nine U.S. Trial Sites HOUSTON, July 13, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Fox Chase Cancer Center in Philadelphia, PA, has been added as an active trial site for the dose-expansion stage of the ongoing clinical trial evaluating the company’s lead drug candidate, seclidemstat, in patients with relapsed or refractory Ewing sarcoma and advanced FET-rearranged sarcomas. The addition of Fox Chase expands to nine the number of active sites participating in the open label trial intended to assess seclidemstat at the recommended Phase 2 dose (RP2D). Patient recruitment is now underway at all sites, and the...

VANCOUVER, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) — TOWER ONE WIRELESS CORP. (CSE: TO) (OTCQB: TOWTF) (Frankfurt: 1P3N) (“Tower One” or the “Company”) an owner and operator of high-quality cellular network infrastructure focused on the development of South American cellular networks, is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). Tower One Wireless commenced trading on the OTCQB with the market open on June 30, 2021, under the symbol “TOWTF”. The OTCQB, operated by OTC Markets Group Inc., is designed for developing and entrepreneurial companies in the United States and abroad. Companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other...

VANCOUVER, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) — Ceylon Graphite Corp. (“Ceylon”) (TSX-V: CYL) (OTC: CYLYF) (FSE: CCY) announces that the original news release captioned “CEYLON GRAPHITE ANNOUNCES MOU FOR JOINT VENTURE WITH STRATEGIC PARTNER TO DEVELOP AND OPERATE ADDITIONAL NEW GRAPHITE MINES AND A LOCAL UPGRADING FACILITY TO MEET GLOBAL BATTERY ANODE NEEDS”, published on July 7, 2021, referred, incorrectly, to LOLC Holdings PLC (LOLC) as Lanka ORIX Leasing Company Group in the first paragraph. With the exit of ORIX Corporation of Japan in March 2018, LOLC Holdings PLC no longer uses its former name Lanka Orix Leasing Company PLC. All other disclosures were correct. After some inquiries from shareholders, Ceylon would like to highlight from the July 7, 2021 press release LOLC intends to purchase up to an aggregate...